All In Biotech

Drug Trial Radar · NCT06511739

A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients

A Phase 2 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients

Last checked: Nov 20, 2026Latest source record: Jul 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 144 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

144

Planned (sponsor's estimate)

Start

May 27, 2024

Primary completion

Aug 1, 2025

Study completion Oct 1, 2025

Sponsor

Sponsor type
Industry
Collaborators
Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd.
First posted
Jul 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A 52-Week Study of SYHX1901 tablet in Adults with non-segmental vitiligo.

Conditions

  • Non-segmental Vitiligo

Interventions

  • SYHX1901Drug

    SYHX1901 tablet

  • placeboDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Facial-Vitiligo Area Scoring Index (F-VASI)Time frame: At 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trials Information Group

    Shijiazhuang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.